InspireMD, Inc. (NSPR) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-03-18
Business type: Asset play
How it makes money
Gross margin rose to 29.5% in 2025 as the U.S. launch of CGuard Prime shifted mix toward direct sales with higher average selling prices.
It generates revenue through two primary channels: direct sales to hospitals in the United States and a network of distributors in over 30 international markets. The business is currently undergoing a shift in its profit profile as it transitions from a distributor-led international model to a direct U.S. model.
While international sales of CGuard EPS grew by $585,000, the U.S. launch of CGuard Prime contributed a $1,385,000 increase in North American revenue. Direct sales in the U.S. carry significantly higher margins because the company captures the full average selling price rather than selling at a discount to distributors.
What protects it: the moat
The MicroNet mesh uses a 23 μm strand to limit embolic debris to 150-180 microns, showing a 0.95% 30-day major adverse event rate.
Its competitive advantage is anchored in the proprietary MicroNet mesh, a biocompatible PET sleeve wrapped around a nitinol stent. Unlike conventional stents, this mesh is designed to prevent "plaque prolapse," where diseased tissue squeezes through the stent struts and travels to the brain, causing a stroke.
Management claims this design provides market-leading protection because it remains on the artery wall permanently, addressing the high risk of embolic showers that occur in the days following a procedure. The efficacy is supported by the C-GUARDIANS pivotal trial, which documented a low 0.95% rate of death, stroke, or myocardial infarction within 30 days.
What growth costs
It spent $16,553,000 on sales and marketing in 2025, a 172.7% increase, to build its direct sales force and Miami headquarters for commercialization.
The company is heavily reinvesting to transition from a research-focused entity to a commercial organization. Selling and marketing expenses nearly tripled in a single year to support the hiring of specialized neurovascular sales personnel in the United States.
In addition to commercial staffing, it must fund ongoing clinical trials to expand its indications. This includes the CGUARDIANS II study for TCAR procedures and CGUARDIANS III for the SwitchGuard neuroprotection system. It also maintains a significant R&D spend, which reached $15,003,000 in 2025 to advance its next-generation carotid and neurovascular platforms.
What could damage it
It lost $48.8 million in 2025 and lacks resources to fund operations for 12 months, creating substantial doubt about its ability to continue.
The primary threat is a capital shortfall before reaching commercial scale. With an accumulated deficit of $302.3 million and a recurring need for external financing, it is entirely dependent on the successful market uptake of CGuard Prime in the U.S. to achieve self-sustainability.
Failure to gain rapid adoption from physicians or setbacks in securing adequate reimbursement from payors would prevent the company from covering its high operating burn rate. This precarious financial state is underscored by an explanatory paragraph from its auditors regarding its ability to continue as a going concern.
About InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.